Skip to main content
Jacobio Pharmaceuticals Group Co., Ltd. logo

Jacobio Pharmaceuticals Group Co., Ltd. — Investor Relations & Filings

Ticker · 1167 HKEX Manufacturing
Open in API
Filings indexed 298 across all filing types
Latest filing 2026-04-09 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 1167

About Jacobio Pharmaceuticals Group Co., Ltd.

http://www.jacobiopharma.com

Jacobio Pharmaceuticals Group Co., Ltd. is a biopharmaceutical company specializing in the in-house discovery and development of innovative oncology therapies. The company is committed to providing breakthrough treatment solutions for patients by focusing its research and development pipeline on six major tumor signaling pathways: KRAS, Tumor Immunity, Tumor Metabolism, P53, RB, and MYC. Jacobio utilizes advanced drug discovery platforms, including induced allosteric mechanisms, to develop novel and improved medicines. The company primarily focuses on developing new drugs at the clinical stage, with the strategic goal of positioning its core projects among the top three globally in their respective therapeutic areas.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2026
Transaction in Own Shares Classification · 1% confidence The document is an HKEX FF301 monthly return detailing movements in the issuer’s share capital and specifically listing multiple share repurchase transactions (shares held as treasury shares). This is a regulatory report on transactions in the company’s own shares. It does not announce new equity financing or an annual/interim report, but rather a series of buy‐back events. Therefore, it falls under Transaction in Own Shares (POS).
2026-04-09 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) reporting changes in issued shares and treasury shares, specifically detailing share repurchases and treasury share holdings. This is a direct report of the company’s transactions in its own shares (buybacks and treasury sales), matching the definition of Transaction in Own Shares (POS).
2026-04-08 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Stock Exchange ‘‘Next Day Disclosure Return’’ (Form FF305) detailing changes in issued shares, treasury shares, and an on-market repurchase report. It discloses the company’s own share buyback activity (treasury share accumulation) including dates, quantities, prices, and balances. This aligns exactly with a Transaction in Own Shares (share repurchase/issuance) filing. Therefore, it should be classified under code POS.
2026-04-02 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Stock Exchange FF305 Next Day Disclosure Return detailing changes in issued shares, treasury shares, and share repurchases (on-market buybacks). It reports the number of shares repurchased, price, and balances of issued and treasury shares. This is a classic disclosure of a company's own share transactions (buyback of treasury shares). According to the filing definitions, this falls under “Transaction in Own Shares” (Code: POS).
2026-03-31 English
VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED $100 MILLION UPFRONT PAYMENT FROM ASTRAZENECA UNDER THE LICENSE AND COOPERATION AGREEMENT FOR THE PAN-KRAS INHIBITOR JAB-23E73
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement informing shareholders of a US$100 million upfront payment under a licensing and collaboration agreement with AstraZeneca. It does not present financial statements or form part of periodic results (so it is not an Earnings Release, Annual, or Interim Report), nor does it involve equity or debt fundraising or capital structure changes (excluding Capital/Financing Update). It also does not announce board changes, dividends, share issues, M&A, or insider transactions. No detailed report is attached or referenced. Therefore this fits the fallback category for general regulatory announcements that do not neatly fit elsewhere: RNS.
2026-03-30 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is Hong Kong Exchange Form FF305 “Next Day Disclosure Return” detailing changes in issued shares and treasury shares, including share repurchases (on-market buybacks), with repurchase dates, prices, quantities, and closing balances. This is a direct report of the company’s purchase of its own shares. It is not an earnings announcement or general regulatory notice but a specific transaction in own shares. Therefore it fits the ‘Transaction in Own Shares’ category.
2026-03-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.